34 results about "Obsessive-compulsive disorders" patented technology

The invention belongs to the technical field of biomedical imaging, and particularly discloses an in-vivo imaging method of an SAPAP3 gene defect disease model, which is characterized in that an effective dose of an S1PR1 receptor targeted radioactive probe is injected into the body of the SAPAP3 gene defect disease model. According to the method, an S1PR1 receptor targeting radioactive probe is utilized, the technical bottleneck that in-vivo and dynamic observation of the S1PR1 receptor cannot be achieved through an existing in-vitro technology is solved, and an indispensable visual tool and a quantitative evaluation means are provided for studying the neurobiological mechanism of related mental diseases such as obsessive-compulsive disorder and accelerating research and development of related drugs.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

A plurality of circular RNAs (circRNAs) the expression of which is correlated with brain disorders. The circRNAs are useful for compositions, kits, assays, and methods for the identification, diagnosis, screening, treatment and / or monitoring of brain disorders including psychiatric disorders such as bipolar disorder (BD), schizophrenia (SCZ), depression, Attention-Deficit / Hyperactivity Disorder (ADHD), Obsessive-compulsive disorder (OCD), Anxiety Disorders, etc., and neurodevelopmental disorders such as Autism, Asperger's Syndrome, and other Autism Spectrum Disorders (ASD), pervasive developmental disorders not otherwise specified (PDD-NOS), etc.

To provide a treatment support device, a treatment support method, and a program capable of facilitating input by a patient and saving time and effort for creating a symptom list and an anxiety hierarchy table in treatment of obsessive-compulsive disease.SOLUTION: The treatment assistance apparatus 1 includes the symptom information acquisition unit 33 that acquires symptom information, which is information about symptoms, from the patient terminal 2 that receives treatment for obsessive-compulsive disease, the anxiety degree information acquisition unit 34 that acquires anxiety degree information, which is information about the relative degree of anxiety of the patient about the symptoms, from the patient terminal 2, and the information acquisition control unit 32 that receives inputs of the symptom information and the anxiety degree information about the symptoms from the patient terminal 2 in parallel.SELECTED DRAWING: Figure 3

A method of treating, preventing or ameliorating at least one symptom of obsessive compulsive disorder (OCD) in a subject is disclosed. The method comprises a step in which a multistrain probiotic formulation is administered to the subject. The multistrain probiotic formulation includes the bacterial strains Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Bifidobacterium breve and Bifidobacterium infantis and Glutamine in a concentration range of 100-500 mg.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The application relates to application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder. The application provides application of Lactobacillus murinus in preparation of a drug for treating obsessive-compulsive disorder, two different OCD mouse models are used to systematically evaluate the intervention effect of Lactobacillus murinus on obsessive-compulsive behavior, and the potential molecular mechanism is preliminarily explored. The results show that the intervention of Lactobacillus murinus can effectively improve the anxiety and obsessive-compulsive behavior of OCD model mice. Further mechanism research finds that the intervention effect may be related to the increase of the activity of excitatory neurons in the medial prefrontal cortex (mPFC) of Lactobacillus murinus.

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt and / or solvate thereof. The present invention also relates to the use of the compound of formula (I) as a drug, in particular for preventing or treating compulsive disorders and related behaviors, including addiction, obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

This invention provides an apophene derivative, its preparation method, and its application. The general formula of the apophene derivative structure described in this invention is shown below: Among them, R 1 C 1 -C 8 alkoxy or hydrogen, R 2 For hydroxyl or hydrogen; R 3 Selected from C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, C 2 -C 10 alkynyl group, C 2 -C 10 alkenyl, halogen, C 1 -C 8 Halogenated, cyano, nitro, or aryl. The use of the 5-hydroxytryptamine 2A receptor agonist and 5-hydroxytryptamine 2C receptor agonist described in this invention in the preparation of medicaments for the prevention and / or treatment of obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes, and drug addiction.

The present disclosure provides a compound of formula (I): JPEG2026506861000048.jpg37170, or a pharmaceutically acceptable salt and / or solvate thereof. The present disclosure also relates to the use of the compounds of formula (I) as pharmaceuticals, in particular for the prevention or treatment of addictions, obsessive-compulsive disorders and related behaviors, including obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

This invention relates to a predictive system for the efficacy of tDCS treatment for obsessive-compulsive disorder (OCD) based on EEG. The system includes a data acquisition and processing module for acquiring resting-state EEG data of the subject; a data preprocessing module for filtering the acquired EEG data and removing signals containing artifacts; a data spectrum analysis and processing module for converting the EEG time-domain signal into a frequency-domain signal using Fast Fourier Transform and dividing it into different frequency bands; and an efficacy prediction processing module for determining the predicted efficacy of tDCS treatment based on the comparison between the subject's characteristic curve and the optimal critical point. This invention also relates to a corresponding method, apparatus, processor, and storage medium. The system, method, apparatus, processor, and storage medium of this invention represent the first method for predicting the efficacy of tDCS treatment for OCD based on EEG. The algorithm has high accuracy and helps solve the key problem of difficulty in selecting treatment methods in clinical diagnosis and treatment.

Provided herein are methods for treating psychiatric disorders by gene therapy (e.g. AAV-directed gene therapy) to deliver and express the human SP4 gene in neuronal cells. Treatable psychiatric disorders include schizophrenia, anxiety, obsessive compulsive disorder, or mood disorder.

The present invention relates to a system and method for managing neurological and psychological disorders, with a specific focus on Obsessive-Compulsive Disorder (OCD). The invention integrates pharmacotherapy, Deep Transcranial Magnetic Stimulation (Deep TMS), and Exposure and Response Prevention (ERP) therapy into a unified framework that addresses the chemical, neurological, and behavioural dimensions of OCD. The system utilizes advanced data analysis and machine learning algorithms to dynamically customize interventions based on patient-specific profiles, ensuring optimal therapeutic efficacy and reduced side effects. The System includes real-time data-driven adjustments, high-intensity engagement protocols, remote monitoring for long-term management, and scalable group therapy capabilities. The system also incorporates advanced neuromodulation technologies and compressed ERP techniques to accelerate behavioural restructuring and neural circuit modulation. By leveraging the synergy between these modalities, the invention provides a holistic and versatile solution for improving patient outcomes, ensuring sustained symptom relief and enhanced quality of life.

Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

Disclosed are methods and apparatuses for treating mental health disorders through electrical stimulation of the carotid sinus nerve (CSN). The systems may include implantable or wearable stimulating electrode arrays configured to preferentially activate baro-afferent fibers of the CSN while minimizing stimulation of chemo-afferent fibers. The stimulation may be delivered in open-loop, closed-loop, or semi-closed-loop modes, with feedback provided by sensors monitoring physiological parameters such as heart rate, blood pressure, respiratory rate, and biochemical markers. The apparatus may include a controller that maps electrode contacts to specific nerve fiber types and dynamically adjusts stimulation parameters to optimize therapeutic outcomes. These systems and methods are designed to address autonomic imbalances associated with neuropsychiatric conditions including depression, anxiety, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD), particularly in patients refractory to conventional therapies.

The present application relates to a method for treating obsessive-compulsive disorder, comprising: a) identifying one or more specific brain regions exhibiting abnormal activation in a subject; and b) targeting the one or more specific brain regions, inhibiting or disrupting neuronal activity in the brain region(s), or interrupting or blocking neuronal signals in the brain region(s) of the subject.

The present invention is directed to the treatment of obsessive-compulsive disorder (OCD) and OCD-related disorders (including body dysmorphic disorder, hoarding disorder, trichotillomania (hair pulling disorder), skin picking disorder, substance / medication-induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders due to another medical condition, and other specified and unspecified obsessive-compulsive disorder and related disorders), tic disorders including Tourette's syndrome, autism spectrum disorder (ASD), and amyotrophic lateral sclerosis (ALS), Parkinson's disease, traumatic brain injury, Provided is a method for treating glutamate excitotoxicity-related disorders, including multiple sclerosis, Huntington's disease, and schizophrenia, comprising administering an effective amount of a histamine type 1 receptor agonist and / or a histamine type 3 receptor antagonist, such as betahistine or a pharmaceutically acceptable salt, analog, metabolite, prodrug, derivative, metabolite, cocrystal, modification, solvate, hydrate, isotope, tautomer, ester, polymorph, or stereoisomer thereof.

Provided are methods of treating neuropsychiatric disorders including obsessive-compulsive related disorders, tic disorders, glutamate excitotoxicity related disorders, autism spectrum disorders, and other medical conditions in patients with a mutation in genes involving function, structure, or plasticity, including but not limited to SHANK3, SAPAP3, NLGN3, NLGN4, NRXN1, CNTNAP2, or MECP2. The methods include administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist or inverse agonist, their pharmaceutically acceptable salts, analogs, metabolites, and prodrugs, including prodrugs of its metabolites, to patients in need of such treatment.

Disclosed herein are methods for treating obsessive-compulsive disorder in a patient in need thereof by administering to the patient a dosage form comprising an effective amount of troriluzole.

The present invention provides methods for treating obsessive-compulsive disorder (OCD) and OCD-related disorders (somatic deformation disorder, hoarding disorder, depilation disorder), scratch (skin scratching) disorder, substance / drug induced obsessive-compulsive disorder and related disorders, obsessive-compulsive disorder and related disorders caused by another medical condition, and OCD-related disorders. And other specified and unspecified obsessive-compulsive disorders and related disorders); a twitch disorder, including Tourette Syndrome; autism spectrum disorder (ASD); and glutamate excitatory toxicity related disorders, including amyotrophic lateral sclerosis (ALS); parkinson's disease; traumatic brain injury; multiple sclerosis; huntington's disease; and schizophrenia, the method comprising administering an effective amount of a histamine type 1 receptor agonist and / or a histamine type 3 receptor antagonist, the invention also relates to a preparation method of the compound, such as betahistine or pharmaceutically acceptable salts, analogs, metabolites, prodrugs, derivatives, metabolites, co-crystals, modifiers, solvates, hydrates, isotopes, tautomers, esters, polymorphs or stereoisomers thereof.

A pharmaceutical composition for treating obsessive-compulsive disorder is provided. The present invention relates to (1) a pharmaceutical composition comprising a dopamine D1 receptor agonist as an effective ingredient for treating obsessive-compulsive disorder, and / or (2) a pharmaceutical composition comprising a dopamine D1 and D2 receptor stimulator, which is administered in combination with a dopamine D2 receptor inhibitor for the purpose of stimulating the dopamine D1 receptor in the striatum, and / or (3) a pharmaceutical composition comprising a dopamine D2 receptor inhibitor, which is administered in combination with a dopamine D1 and D2 receptor stimulator.

Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessivecompulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

The present invention relates to the use of HIP / PAP proteins or derivatives thereof in therapy and prophylaxis, in particular to the use of said HIP / PAP proteins or derivatives thereof in the treatment of cognitive disorders associated with one or more anxiety disorders in an individual in need thereof, and for improving cognitive function in an individual affected by a nervous system condition associated with one or more anxiety disorders, or for alleviating cognitive deficits in a subject suffering from a condition selected from the group consisting of obsessive-compulsive disorder, attention deficit disorder, Lewy body dementia, early onset dementia, epilepsy-related cognitive dysfunction, frontotemporal dementia, posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar affective disorder, substance abuse, attention deficit disorder, etc. A psychiatric disorder and an SARS-CoV-2 infection; and for the prevention and / or treatment of diet-induced cognitive and anxiety deficits in an individual in need thereof, in particular for the prevention and / or treatment of cognitive and anxiety deficits caused by high fat diet.

The invention provides an acupoint electrical stimulation device for adjuvant therapy of obsessive-compulsive disorder, which comprises a first watchband and a second watchband, one end of the first watchband and one end of the second watchband are connected with a massage seat, the massage seat is provided with a pulse magnetic moxibustion sheet, one side of the first watchband is provided with an air bag strip, two ends of the air bag strip are respectively and fixedly connected with an elastic band, and the elastic bands are connected with the first watchband and the second watchband. The two elastic belts form a group, the two ends of the air bag strip are respectively provided with a group of elastic belts, and each group of elastic belts are respectively arranged at the two ends of the air bag strip; the first watchband and the second watchband are matched with the massage seat to form a wearable structure, the wearable structure can adapt to wrist sizes of different users, the airbag strip is installed on the fixed-length watchband, it is ensured that when acupuncture point stimulation is carried out, the airbag strip fills a gap between an arm and the watchband in the watchband wearing process, and the user experience is improved. The pulse magnetic moxibustion sheet and the massage head are stably attached to the skin in the using process of the device, and the acupuncture point stimulation effect is prevented from being affected by looseness.

Modified release tablet dosage forms comprising tolcapone are disclosed. The tablet dosage forms provide a pulsed, pH dependent release profile of tolcapone to both the gastric space and the small intestine. Methods of treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's Disease and obsessive compulsive disorder using said dosage forms are provided.

A treatment support device 1 comprises: a symptom information acquisition unit 33 that acquires symptom information, which is information related to a symptom, from a patient terminal 2 used by a patient receiving treatment for obsessive-compulsive disorder; an anxiety level information acquisition unit 34 that acquires anxiety level information, which is information related to the patient's relative level of anxiety regarding the symptom, from the patient terminal 2; and an information acquisition control unit 32 that, when acquiring the symptom information and the anxiety level information related to the symptom, receives respective inputs in parallel from the patient terminal 2.

The present invention relates to methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders including obsessive compulsive disorder (OCD), Alzheimer's disease psychosis or psychosis in Alzheimer's disease (AD-P), frontotemporal dementia (FID), behavioral and psychological symptoms in dementia, motor symptoms in Parkinson's disease, and behavioral and psychological symptoms in Parkinson's disease, with (R)-1- (5-methoxy-1H-indol-1-y1)-N,N-dimethylpropan-2-amine (zalsupindole; AAZ-A-154). or a pharmaceutically acceptable salt or solvate thereof.